Eli Lilly Stock Drops Amid Reduced Guidance, Weight-Loss Drug Market Concerns

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2025-07-30 05:27:02

BTCCSquare news:

Eli Lilly shares fell nearly 6% Tuesday, underperforming the broader market's slight decline. The drop followed Novo Nordisk's downward revision of its 2024 sales and operating profit forecasts, sparking concerns about the competitive weight-loss drug sector where Lilly's Zepbound recently gained approval.

The pharmaceutical giant had ridden a wave of Optimism since entering the obesity treatment market late last year. However, sector leader Novo Nordisk's guidance cut – reducing sales growth projections from 13-21% to 8-14% – cast a shadow over the entire GLP-1 drug category. Investors appear worried about potential headwinds for Lilly's competing treatments despite their strong initial reception.

By:

Log in to Reply

Globe Life Stock Surges 7% as Regulatory Probe Ends and Analysts Turn Bullish

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.